Paracetamol Dosing for PDA Closure in Infants
For hemodynamically significant patent ductus arteriosus (hsPDA) closure in preterm infants, intravenous paracetamol at 15 mg/kg every 6 hours for 3-5 days is the most commonly used and evidence-supported regimen, though lower doses (7.5-10 mg/kg every 6 hours) appear equally effective with potentially reduced drug exposure.
Standard Dosing Regimen
The conventional dose that has been most extensively studied is:
- 15 mg/kg/dose intravenously every 6 hours for 3-5 days 1, 2, 3, 4
- This regimen achieves ductal closure in 78-100% of cases across multiple studies 1, 2, 3
- Treatment should be initiated when hsPDA is diagnosed, typically between 18-24 hours to 14 days of postnatal age 2, 4
Low-Dose Alternative
Recent evidence demonstrates that reduced dosing is non-inferior:
- Initial dose of 15 mg/kg, then 7.5 mg/kg every 6 hours achieved 96% closure rate 1
- 10 mg/kg every 6 hours for 72 hours achieved 92% closure rate, non-inferior to conventional dosing 4
- Lower doses may reduce total drug exposure while maintaining efficacy, particularly important given concerns about hepatotoxicity 1, 4
Target Population
Paracetamol is used in:
- Preterm infants <32 weeks gestation with echocardiographically confirmed hsPDA 1, 2
- Very preterm infants <30 weeks requiring mechanical ventilation or CPAP with FiO2 ≥0.35 4
- Birth weights typically 1000-1650g, though lower weights have been treated 2
Treatment Duration and Monitoring
- Standard course: 3-5 days depending on protocol 1, 2, 3, 4
- Echocardiographic reassessment after completion of treatment course 1, 2
- Some units perform routine blood monitoring and paracetamol levels during treatment, though this varies widely (44% of UK units) 5
- Median paracetamol levels are comparable between low and conventional doses 1
Efficacy Considerations
Paracetamol is less effective than ibuprofen for complete ductal closure (52% vs 78%, P=0.026), but achieves similar ductal constriction rates (81% vs 90%) 3. This suggests:
- Paracetamol may be used as first-line therapy, particularly when NSAIDs are contraindicated 3
- The constriction effect is clinically meaningful even when complete closure is not achieved 3
- Ibuprofen remains first-line in 92% of UK neonatal units, with paracetamol used in only 33% 5
Important Caveats
Extremely preterm infants (<27 weeks gestation) show reduced response to paracetamol, suggesting this population may require alternative dosing strategies or different therapeutic approaches 6.
The need for second-course treatment or rescue therapy occurs in approximately 3.5-21% of cases, with no significant difference between low and conventional doses 1.
Safety Profile
- No serious adverse events reported in recent trials 1, 2, 3, 4
- Mortality and other neonatal morbidities comparable between dosing regimens 1
- Significantly safer than NSAIDs regarding gastrointestinal perforation, bleeding, and renal failure 2
Practical Algorithm
- Confirm hsPDA by echocardiography in preterm infant <32 weeks
- Choose dosing regimen:
- Standard: 15 mg/kg IV q6h for 3-5 days
- Low-dose: 15 mg/kg initial, then 7.5-10 mg/kg IV q6h for 3 days
- Reassess by echo after treatment completion
- If persistent hsPDA: Consider second course or alternative therapy (ibuprofen)
- Monitor for adverse effects, though routine labs not universally required